Niramai wins at the 5th Commonwealth Digital Health Awards

We are happy to announce Niramai’s victory at the Commonwealth Digital Health Awards in the category of non-communicable diseases.

Niramai Health Analytix, India’s foremost and innovative AI-based breast cancer screening company has won the 5th Commonwealth Digital Health Awards in the category of non-communicable disease. 

The event celebrates digital innovations and encourages health and well-being transformation for individuals. The 5th edition of this event provided a launch pad for medical innovations to reach the next level amidst the new normal. The vision of the Commonwealth Center for Digital Health is that all Commonwealth nations should have affordable access to the benefits of Digital Health solutions and services. 

Niramai’s flagship product ‘Thermalytix’ uses a high-resolution thermal sensing device and a cloud-hosted analytics solution for analyzing thermal images using data analytics and artificial intelligence for reliable, early, and accurate breast cancer screening. NIRAMAI’s solution has led to 26 granted patents with 11 US patents and others across India, Singapore, China, and Canada. Niramai’s thermal screening facility is an experience that is non-invasive, painless, radiation-free, and generates screening reports immediately. The screening can be done any number of times and without any age restriction as it is radiation-free and can be used to detect lumps or abnormalities in the breast at an early stage. 


Dr. Geetha Manjunath, Founder & CEO, of Niramai, said,


“I am delighted to receive this Global Common Wealth Digital Health Award on behalf of NIRAMAI. We thank the organizing committee for creating this platform to showcase health tech innovation and the jury for recognizing the importance of our affordable, accessible, non-invasive privacy-aware method of screening for breast cancer. All the credits of this award goes to the passionate Niramai team who are consistently and persistently trying to solve this problem since the last 6 years. We thank our mentors, investors, and well-wishers for supporting us throughout this journey. Breast cancer is curable, so let us all work together to stop deaths caused due to it.”



Read More

Punjab partners with Niramai to become the 1st state to offer contactless breast cancer screening

June 14, 2022

Announcing our partnership with the Punjab Government in collaboration with Roche Pharma India

It is with great pride and honor that we announce Niramai’s partnership with the Punjab Government to contribute to women’s breast health awareness. 

It is with great pride and honor that we announce Niramai’s partnership with the Punjab Government to contribute to women’s breast health awareness. 

Niramai’s novel Artificial Intelligence-based, radiation-free, automated, non-invasive breast health screening test is called ThermalytixTM. It is a no-touch, no pain, a radiation-free privacy-sensitive screening test that detects breast cancer at an early stage for women of all age groups, whether symptomatic or asymptomatic.

The Punjab government advances the use of ThermalytixTM thus making Punjab the 1st state to offer contactless breast cancer screening and a joint initiative for the same has been commenced. The partnership named “Punjab Breast Cancer AI Digital project”, also known as the ‘Pink project’ is a collaboration among 3 operational institutions with distinctive allotted roles as follows:

  1. Niramai Health Analytix caters as the breast health screening partner
  2. Roche India contributes as a referral pathway technical partner
  3. And the Health Department, Govt. of Punjab is the initiator and fund supporter

This partnership project aims to accelerate breast health awareness through breast screening thus intending to downstage breast Cancer in the state of Punjab. It aids in increasing awareness towards early detection and management of breast cancer. 

Roche Products India Limited plays a vital role in this initiative and will act as a Technical Partner for project planning, implementation & monitoring of the state-wide Breast Cancer project plan, thereby strengthening the referral pathway through digitization. 

Early detection of Breast Cancer is extremely crucial to reduce mortality rates and provide appropriate treatment pathways on time. This approach intends on screening 15,000 women in a span of one year to accelerate the early-stage diagnosis of breast cancer. Since Niramai’s ThemalytixTM is a low-cost and portable breast screen test, it can be used as the primary screening method conducted by technicians with minimal training in resource-constrained locations as well. 

The Punjab government will ensure the mobilization of the population for screenings which would be supported by Niramai Health Analytix & Roche Pharma India. The Punjab screening camp commenced on 15th June 2022 and was inaugurated in presence of:

Director Family Welfare (DFW): Dr. Ranjit Singh Ghotra
Civil Surgeon, District Mohali: Dr. Adarshpal Kaur
Dr. Sandeep (State Programme Officer &Assistant Director, NPCDCS and His team.

Read More

Niramai gets US FDA clearance for their first medical device, SMILE-100 System

US markets now open for the Innovative Indian Startup

Bengaluru, 14 March, 2022: Niramai Health Analytix, the deep-tech Bangalore-based healthcare company offering a novel radiation-free, non-touch, accurate, breast cancer screening solution in India, has now received US FDA clearance for their first device called SMILE-100 System. The SMILE-100 System is a breast thermography device that helps a healthcare personnel to review, measure and analyze thermally significant indications in the breast region. It can be used in the hospital, acute care settings, outpatient surgery, healthcare practitioner facilities or an environment where patient care is provided by qualified healthcare personnel. It is intended for use as adjunctive diagnostic imaging for thermally significant indications in the breast region.  

The SMILE-100 System assists experts to visualize high thermal activity patterns clearly demarcated on thermal images as hotspots and can enable healthcare professionals to make better decisions in breast cancer screening and diagnosis.  Another unique feature of SMILE-100 is use of their patented artificial intelligence-based algorithms to check the quality of input thermal images, which can greatly reduce the errors in thermal image capture and enable low skilled health workers to confidently perform the imaging. 

Dr. Geetha Manjunath, CEO and Founder of Niramai, said, “We are super excited to announce the FDA 510(k) clearance of SMILE-100 System. A proud moment for the team. It was a great learning experience to go through the very rigorous US regulatory process. This win further validates the intrinsic power of NIRAMAI team and has given us the confidence that we can build many more such world-class medical devices of high quality and help reduce untimely deaths due to cancer.”

Niramai is a pioneer in the breast cancer screening with 26 granted international patents. An US FDA approved device is a marquee asset for any Indian health-tech company. In fact, Niramai is the first Indian company to get an US FDA clearance for a medical device used for women health. Last year, the company announced European CE approval for their Thermalytix™ Solution and have already started pilots in multiple European countries. This FDA approval will now give Niramai a tool to foray into the US market and beyond.

Dr Kiran Mazumdar Shaw, the global biotech business leader and Biocon chairperson appreciated this news and said “I congratulate Geetha and her team for this tremendous achievement. Niramai is one of the very few deeptech startups from India which has obtained both European and US clearance for their innovative medical device. Indian startups are solving important healthcare problems that is the need of the hour today. Such milestones of innovation showcase the power of Indian women-led companies to the rest of the world”.

Mr. Manish Singhal, Founding Partner of pi Ventures and the lead investor of Niramai who has been part of their journey since 2017, commented, “In the last five years, we have seen Niramai grow in every aspect – product innovation, team strength, clinical provenance, product adoption and international recognition. I congratulate the team for this exciting win of the FDA clearance for their SMILE-100 System. It’s a great feat for any Indian Startup to get US approval for their medical device. This can be the key inflection point for the company to take their product truly global saving lives all the world.”

NIRAMAI has now created its own reputed brand in India with their innovative breast health products.  Partnering with experienced radiologists and reputed hospital / diagnostic chains in India such as Apollo Clinics, HCG Cancer Hospitals, Rainbow Hospitals among others, Niramai provides breast screening services across 19 cities in India.  Niramai also conducts large scale screening camps in association with Karnataka Cancer Society, Rotary International and other socially concerned organizations. With the FDA cleared SMILE-100 System and CE approved Thermalytix products, the company is now taking their Made-in-India innovation to global scale.

——

About Niramai Health Analytix:

NIRAMAI Health Analytix is a deep-tech healthcare company offering a novel Artificial Intelligence-based devices. Their flagship product is Thermalytix which is radiation-free, non-touch, accurate, breast cancer screening test for women of all age groups. The solution is portable, automated and detects breast cancer at a much earlier stage than traditional screening methods. NIRAMAI was co-founded in July 2016 by Dr. Geetha Manjunath and Ms Nidhi Mathur. NIRAMAI has so far raised a total of $7M from institutional investors from India, Japan and Singapore. Investors include Dream Incubator, BeeNext, pi Ventures, Ankur Capital, Axilor Ventures, 500 Startups, and others.  NIRAMAI has won many international prestigious awards including World Bank instituted Global Women HealthTech Award 2022, National Startup Award 2020 in India, the Gold prize in Hack Osaka 2019 in Japan and and have received research funding from the Bill & Melinda Gates Foundation and CDC UK. Niramai also conducts regular free webinars and awareness talks on breast health and provides a free breast health helpline on Whatsapp number on +91-9483434444.

Read More

Niramai receives CE Mark – Regulatory approval for Europe

Bengaluru-based healthtech startup Niramai Health Analytix’s patented, radiation-free breast cancer screening solution, Thermalytix™, has received CE mark approval, ISO 13485, and MDSAP (Medical Device Single Audit Programme) International Certifications.

Read more at: https://yourstory.com/2021/04/healthtech-startup-niramai-set-expand-global-markets

Read More